Arbutus Biopharma (ABUS) announced its 2025 corporate objectives and provided a financial update. The Company had cash, cash equivalents and investments in marketable securities totaling ...

WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the upcoming retirement of its co-founder and Chief ...

Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on Arbutus Biopharma (ABUS – Research Report), retaining the price target of $5.00. Discover outperforming stocks and invest ...

Arbutus Biopharma is also venturing into the application of AB-101, their novel Oral PD-L1 Inhibitor. The PD-L1 Inhibitor trial is planned in two parts, in which both healthy and HBV-infected ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise ...